Ximelagatran: A new era in oral anticoagulation

Journal of Pharmacy Technology

Volumn 19, Issue 4, 2003, Pages 222-228

  McCall, Kenneth L ^a   MacLaughlin, Eric J ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY; PHARMACODYNAMICS; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 0038043582     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250301900304     Document Type: Review

References (35)

1. National Center for Health Statistics. Births, marriages, divorces, and deaths: provisional data for September 2001. Natl Vital Stat Rep 2002;50(8):1-3.
2. Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial (abstract). J Gen Intern Med 1997;12:66.
3. Holm T, Lassen JF, Husted SE. Identification and surveillance of patients on oral anticoagulation therapy in a large geographical area - use of laboratory information systems. Thromb Haemost 1999;82(suppl):858-9.
4. Osende J, Zaman A, Rodriguez O, Carlsson S, Fuster V, Badimon JJ. Antithrombotic effects of melagatran, a new direct thrombin inhibitor in an ex-vivo pig model of arterial thrombosis (abstract). Presented at: XVIII Congress of The International Society on Thrombosis and Haemostasis, Paris, July 6-12, 2001.
5. Bostrom SL, Dagnelid E, Ulvinge JC. Inhibition of thrombin generation by melagatran via the inhibition of factor V activation (abstract). Presented at: XVIII Congress of The International Society on Thrombosis and Haemostasis, Paris, July 6-12, 2001.
6. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects (abstract). Thromb Haemost 2002;87:300-5.
7. Nylander S, Mattsson C. Inhibition of thrombin-induced platelet activation by different anticoagulants as measured with flow cytometry (abstract). Blood 2000;96(11 pt 2):50b.
8. Schersten F, Wahlund G, Carlsson S, Mattsson C, Grip L. Effect of melagatran, the active form of the oral direct thrombin inhibitor, H 376/95, on platelet deposition and relative thrombus size in a porcine, coronary artery ober-stretch injury model (abstract). Circulation 2000;102(suppl II):II-130.
9. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999;94:187-97.
10. Carlsson S, Elg M. A comparison of ximelagatran and warfarin on thrombus size during phophylaxis of a vena cava thrombosis in the anesthetized rat (abstract). Presented at: American Society of Hematology 43rd Annual Meeting, Orlando, FL, December 7-11, 2001.
11. Eriksson UG, Eriksson LM, Ohlsson L, Wåhlander K. Mild-to-moderate liver impairment has no influence on the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (abstract). Clin Pharmacol Ther 2002;71:P99.
12. Johansson LC, Eriksson UG, Frison L, Fager G. A comparison of the pharmacokinetics of ximelagatran in young and elderly healthy subjects (abstract). Blood 2000;96(11 pt 1):57a.
13. Johansson LC, Eriksson UG, Frison L, Fager G. The impact of ethnic origin on the pharmacokinetics of orally administered ximelagatran (abstract). Blood 2000;96(11 pt 1):56a.
14. Eriksson UG, Wollbratt M, Wolzt M, Svensson M, Grind M. Comparison of the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in patients with nonvalvular atrial fibrillation and elderly healthy subjects (abstract). Clin Pharmacol Ther 2002; 71:P95.
15. Cullberg M, Eriksson H, Eriksson UG, Frison L, Karlsson MO, Schulman S, et al. Pharmacokinetics of melagatran after oral dosing with ximelagatran, a direct thrombin inhibitor, in patients with acute venous thromboembolism (VTE) (abstract). Clin Pharmacol Ther 2002;71:P61.
16. Eriksson UG, Frisson L, Gustafsson D, Mandema J, Karlsson MO, Eriksson B. Pharmacokinetics of melagatran, the active form of the oral, direct thrombin inhibitor H376/95, in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism (abstract). Blood 2000;96(11 Part 2):93b.
17. Sarich TC, Teng R, Peters G, Wollbratt M, Homolka B, Svensson M, et al. Lack of an effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran (abstract). American Society of Hematology 43rd Annual Meeting. Orlando, Florida. December 7-11, 2001.
18. Johansson S, Eriksson UG, Samuelsson O, Attman P, Mulec H, Frison L, et al. The influence of severe renal impairment on the pharmacokinetics of oral ximelagatran and subcutaneous melagatran (abstract). Clinical Pharmacology & Therapeutics 2002;71(2):P96.
19. Package insert. Coumadin (warfarin sodium) Princeton, NJ: Bristol-Myers Squibb Company, June 2002.
20. Johansson S, Eriksson LM, Thuresson A, Larsson M, Frison L, Bylock A, et al. Ximelagatran, an oral direct thrombin inhibitor, has no effect on the pharmacokinetics of P450-metabolized drugs (abstract). Clin Pharmacol Ther 2002;71:P65.
21. Eriksson UG, Fager G, Eriksson LM, Cullberg M, Frison L, Bylock A, et al. Effect of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, active form of the oral direct thrombin inhibitor H 376/95 (abstract). Clin Pharmacol Ther 2002;69(Suppl S):P24.
22. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study. Arch Intern Med 2001;161:2215-21.
23. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared to dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002;87(2):231-7.
24. Eriksson BI, Lindbratt S, Kalebo P, Bylock A, Frison L, Welin L, et al. METHRO II: dose-response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement (abstract). Haemostasis 2000;30(suppl 1):20-1.
25. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-96.
26. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. The oral direct thrombin inhibitor ximelagatran and its subcutaneous (sc) form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement (THR or TKR): The EXPRESS study (abstract). Presented at: American Society of Hematology 44th Annual Meeting. Philadelphia, December 6-10, 2002.
27. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002;137:648-55.
28. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) (abstract). Presented at: American Society of Hematology 44th Annual Meeting. Philadelphia, December 6-10, 2002.
29. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Eriksson H. Thrive IV: An open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran (abstract). Presented at: American Society of Hematology 43rd Annual Meeting. Orlando, FL, December 7-11, 2001.
30. Schulman S, Eriksson H, Lapidus L, Olsson C, Welin L, Frison L, et al. Efficacy and tolerability of the oral direct thrombin inhibitor ximelagatran for the treatment of venous thromboembolism (abstract). J Gen Intern Med 2002;17(suppl 1):131.
31. Eriksson H, Wåhlander K, Lundström T, Clason SB, Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial (abstract). Presented at: American Society of Hematology 44th Annual Meeting. Philadelphia, December 6-10, 2002.
32. Petersen P. First experience with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (abstract). J Gen Intern Med 2001;16(suppl 1):164.
33. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119(suppl):194S-206S.
34. Petersen P. A 2-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (abstract). Neurology 2002;58(suppl 3):a477.
35. Halperin JL. SPORTIF III: a long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (abstract). Presented at: American College of Cardiology 52nd Annual Scientific Session, Chicago, April 2, 2003.